A Randomized Phase II Study of Fulvestrant in Combination with the dual mTOR Inhibitor AZD2014 or Everolimus or Fulvestrant alone in Estrogen Receptor-Positive Advanced or Metastatic Breast Cancer

Trial Profile

A Randomized Phase II Study of Fulvestrant in Combination with the dual mTOR Inhibitor AZD2014 or Everolimus or Fulvestrant alone in Estrogen Receptor-Positive Advanced or Metastatic Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Aug 2017

At a glance

  • Drugs Fulvestrant (Primary) ; Vistusertib (Primary) ; Everolimus
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms MANTA
  • Most Recent Events

    • 25 Aug 2017 Planned End Date changed from 1 Apr 2017 to 1 Jun 2019.
    • 25 Aug 2017 Planned primary completion date changed from 1 Jun 2016 to 1 Jun 2019.
    • 25 Aug 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top